Orphan Drugs and Big Pharma Strategy : The Curious Case of Humira / David O. Hartman, Mary E. Schramm.

Format:

Book

Author/Creator:

Hartman, David O., author.

Schramm, Mary E., author.

Series:

SAGE business cases.

SAGE business cases

Language:

English

Subjects (All):

Abbott Laboratories--Reorganization--Case studies.

Abbott Laboratories.

Health care rationing.

Physical Description:

1 online resource

Place of Publication:

London : Society for Case Research, 2025.

Summary:

On January 1, 2013, Abbott Laboratories, one of the most recognized American pharmaceutical companies, split itself into two companies: Abbott and AbbVie Inc. Abbott retained the original company name and a diverse group of health care products, including medical devices, diagnostic tests and instruments, and nutritional products. AbbVie received all of Abbott's big-name drugs, including the blockbuster anti-inflammatory Humira. Abbott CEO Miles White indicated that investors would benefit from the two fundamentally different investment opportunities with distinct strategic profiles and business priorities. The financial community was divided as to which company would prove to be the better long-term investment decision for investors. The fundamental issue that drove the break-up was the future revenue prospects of Humira. These prospects hinged on Humira's status as an orphan drug and the ability of AbbVie to acquire additional FDA approved indications for its use. The case is most appropriate for use in upper-level undergraduate and graduate courses in strategy, health management, and public policy.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

9781071979433

1071979434

OCLC:

1483993383